Aldoxorubicin: Additional Phase II data

Additional data from 9 HIV-infected patients with Kaposi’s sarcoma in an open-label, U.S. Phase II trial showed that IV aldoxorubicin led to 7 partial responses within 4 months of the end of study vis...